Many diseases are transmitted from different animals and other living organisms to humans, including worms, fungi, mammals and reptiles. These are mainly diseases that result from the attack of various microbes on the human body. However, many diseases in animals and plants are not transmitted to humans.

These diseases, such as the “avian flu”, malaria, bilharzia, rabies, the neurological “mad-cow” disease, and recently the coronavirus (COVID-19), originate from animals. And humans are infected with them from these animals. Combating microbes shows that these almost uncurable diseases arise from the entry of the microbes into the human body. The complications caused, in many cases due to a failure of the immune system, are a source of concern. To this day, the Ahoshi race has managed to maintain its existence. But the microbial talent of rapid genetic changes and the creation of mutations. The complexities of the human immune system. They are a significant challenge to the laws and the developers of drugs, vaccines, and other drugs. Only the unification of forces and the transfer of knowledge between the people of Eden can overcome these attacks of the various microbes. But even these days, diseases such as the flu, malaria, and mad cow disease remain, with only partial solutions.

References

1. SS Morse. "Factors in the emergence of infectious diseases". Emerging Infectious Diseases 1 (1995): 7-15.
2. Albert Osterhaus. "Catastrophes after crossing species barriers". Philosophical Transactions of the Royal Society B 356 (2001): 791-793.
3. Jean C Manson and Abigail B Diack. "Evaluating the Species Barrier". ©2016 Food Safety Commission, Cabinet Office, Government of Japan (2016).
4. Will RG., et al. “A new variant of Creutzfeldt-Jakob disease in the UK”. Lancet 347 (1996): 921-925.
5. McGovern G., et al. “Influence of breed and genotype on the onset and distribution of infectivity and disease-associated prion protein in sheep following oral infection with the bovine spongiform encephalopathy agent”. Journal of Comparative Pathology 152 (2015): 28-40.
6. Rubenstein R and Chang B. “Re-assessment of PrPSc distribution in sporadic and variant CJD”. PLoS ONE 8 (2013): e66352.
7. Wadsworth JDF., et al. “Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay”. The Lancet 358 (2001): 171-180.
8. Ramasamy I., et al. “Organ distribution of prion proteins in variant Creutzfeldt-Jakob disease”. The Lancet Infectious Diseases 3 (2003): 214-222.
9. Franz M., et al. “Detection of PrPSc in peripheral tissues of clinically affected cattle after oral challenge with bovine spongiform encephalopathy”. Journal of General Virology 93 (2012): 2740-2748.
10. Houston F., et al. “Transmission of BSE by blood transfusion in sheep”. Lancet 356 (2000): 999-1000.
11. Hunter N., et al. “Transmission of prion diseases by blood transfusion”. Journal of General Virology 83 (2002): 2897-2905.
12. Baeten LA., et al. “A natural case of chronic wasting disease in a free-ranging moose (Alces alces shirasi)”. Journal of Wildlife Diseases 43 (2007): 309-314.
13. McCutcheon S., et al. “All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD”. PLoS One 6 (2011): e23169.
14. Andréoletti O., et al. “Highly efficient prion transmission by blood transfusion”. PLOS Pathogens 8 (2012): e1002782.
15. Hewitt PE., et al. “Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components”. Vox Sanguinis 91 (2006): 348.
16. Peden AH., et al. “Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient”. Lancet 364 (2004): 527-529.
17. Andréoletti O., et al. “Highly efficient prion transmission by blood transfusion”. PLOS Pathogens 8 (2012): e1002782.
18. Angers RC., et al. “Chronic wasting disease prions in elk antler velvet”. Emerging Infectious Diseases 15 (2009): 696-703.
19. Race B., et al. “Prion infectivity in fat of deer with chronic wasting disease”. Journal of Virology 83 (2009): 9608-9610.
20. Mathiason CK., et al. “Infectious prions in the saliva and blood of deer with chronic wasting disease”. Science5796 (2006): 133-136.
21. Dhama K., et al. “SARS-CoV-2 jumping the species barrier: zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus”. Travel Medicine and Infectious Disease (2020).
22. Nicole Nova. "Cross-Species Transmission of Coronaviruses in Humans and Domestic Mammals, What Are the Ecological Mechanisms Driving Transmission, Spillover, and Disease Emergence?" Frontiers in Public Health 9 (2021): 717941.
23. Kumar R., et al. “COVID-19 and Domestic Animals: Exploring the Species Barrier Crossing, Zoonotic and Reverse Zoonotic Transmission of SARS-CoV-2”. Current Pharmaceutical Design9 (2021): 1194-1201.
24. World Health Organization (WHO) (2020a) Coronavirus Disease 2019 (COVID-19) Situation Report (2020).
25. Lai CC., et al. “Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths”. Journal of Microbiology, Immunology and Infection 53 (2020): 404-412.
26. Wu JT., et al. “Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China”. Nature Medicine 26 (2020): 506-510.
27. Rosenbaum L. “Facing COVID-19 in Italy-Ethics, Logistics and Therapeutics on the epidemic's front line”. The New England Journal of Medicine 382 (2020): 1873-1875.
28. Rajgor DD., et al. “The many estimates of the COVID-19 case fatality rate”. The Lancet Infectious Diseases 20 (2020): 776-777.
29. World Health Organization (WHO) (2020b) COVID-19 Situation Report-142 (2020).
30. Griffin JF. “A strategic approach to vaccine development: Animal models, monitoring vaccine efficacy, formulation and delivery”. Advanced Drug Delivery Reviews 54 (2002): 851-861.
31. Gralinski LE and Menachery VD. “Return of the coronavirus: 2019-nCoV”. Viruses 12 (2020): 135.
32. Muhamood Moothedath., et al. “COVID and Animal Trials: A Systematic Review". Journal of Pharmacy and Bioallied Sciences1 (2021): S31-S35.